1932
0
  1. Home
  2. A-Z Publications
  3. Annual Review of Public Health
  4. Volume 40, 2019
  5. Article

Annual Review of Public Health

Volume 40, 2019

Causes and Patterns of Dementia: An Update in the Era of Redefining Alzheimer's Disease

Abstract

The burden of dementia continues to increase as the population ages, with no disease-modifying treatments available. However, dementia risk appears to be decreasing, and progress has been made in understanding its multifactorial etiology. The 2018 National Institute on Aging–Alzheimer's Association (NIA-AA) research framework for Alzheimer's disease (AD) defines AD as a biological process measured by brain pathology or biomarkers, spanning the cognitive spectrum from normality to dementia. This framework facilitates interventions in the asymptomatic space and accommodates knowledge that many additional pathologies (e.g., cerebrovascular) contribute to the Alzheimer's dementia syndrome. The framework has implications for how we think about risk factors for “AD”: Many commonly accepted risk factors are not related to AD pathology and would no longer be considered risk factors for AD. They may instead be related to other pathologies or resilience to pathology. This review updates what is known about causes, risk factors, and changing patterns of dementia, addressing whether they are related to AD pathology/biomarkers, other pathologies, or resilience.

Keyword(s): Alzheimer's disease, biomarkers, cognition, dementia, epidemiology, neuropathology
Loading

Article metrics loading...

/content/journals/10.1146/annurev-publhealth-040218-043758
2019-04-01
2024-04-19
Loading full text...

Full text loading...

/deliver/fulltext/publhealth/40/1/annurev-publhealth-040218-043758.html?itemId=/content/journals/10.1146/annurev-publhealth-040218-043758&mimeType=html&fmt=ahah

Literature Cited

  1. 1. 
    Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA et al. 2008. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch. Neurol. 65:1509–17
     [Google Scholar]
  2. 2. 
    Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH et al. 2011. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7:270–79
     [Google Scholar]
  3. 3. 
    Alzheimer Dis. Int. 2013. The global impact of dementia 2013–2050 Policy Brief, Alzheimer Dis. Int London: https://www.alz.co.uk/research/GlobalImpactDementia2013.pdf
  4. 4. 
    Alzheimer's Assoc. 2018. 2018 Alzheimer's disease facts and figures. Alzheimer's Dement 14:367–429
     [Google Scholar]
  5. 5. 
    Arenaza-Urquijo EM, Vemuri P 2018. Resistance versus resilience to Alzheimer disease: clarifying terminology for preclinical studies. Neurology 90:695–703
     [Google Scholar]
  6. 6. 
    Arfanakis K, Wilson RS, Barth CM, Capuano AW, Vasireddi A et al. 2016. Cognitive activity, cognitive function, and brain diffusion characteristics in old age. Brain Imaging Behav 10:455–63
     [Google Scholar]
  7. 7. 
    Arnold SE, Louneva N, Cao K, Wang LS, Han LY et al. 2013. Cellular, synaptic, and biochemical features of resilient cognition in Alzheimer's disease. Neurobiol. Aging 34:157–68
     [Google Scholar]
  8. 8. 
    Arvanitakis Z, Leurgans SE, Barnes LL, Bennett DA, Schneider JA 2011. Microinfarct pathology, dementia, and cognitive systems. Stroke 42:722–27
     [Google Scholar]
  9. 9. 
    Arvanitakis Z, Schneider JA, Wilson RS, Li Y, Arnold SE et al. 2006. Diabetes is related to cerebral infarction but not to AD pathology in older persons. Neurology 67:1960–65
     [Google Scholar]
  10. 10. 
    Azarpazhooh MR, Avan A, Cipriano LE, Munoz DG, Sposato LA, Hachinski V 2018. Concomitant vascular and neurodegenerative pathologies double the risk of dementia. Alzheimers Dement 14:148–56
     [Google Scholar]
  11. 11. 
    Baker LD, Bayer-Carter JL, Skinner J, Montine TJ, Cholerton BA et al. 2012. High-intensity physical activity modulates diet effects on cerebrospinal amyloid-β levels in normal aging and mild cognitive impairment. J. Alzheimers Dis. 28:137–46
     [Google Scholar]
  12. 12. 
    Barnard ND, Bush AI, Ceccarelli A, Cooper J, de Jager CA et al. 2014. Dietary and lifestyle guidelines for the prevention of Alzheimer's disease. Neurobiol. Aging 35:Suppl. 2S74–78
     [Google Scholar]
  13. 13. 
    Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A et al. 2012. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 367:795–804
     [Google Scholar]
  14. 14. 
    Beecham GW, Hamilton K, Naj AC, Martin ER, Huentelman M et al. 2014. Genome-wide association meta-analysis of neuropathologic features of Alzheimer's disease and related dementias. PLOS Genet 10:e1004606
     [Google Scholar]
  15. 15. 
    Beeri MS, Haroutunian V, Schmeidler J, Sano M, Fam P et al. 2012. Synaptic protein deficits are associated with dementia irrespective of extreme old age. Neurobiol. Aging 33:1125.e1–8
     [Google Scholar]
  16. 16. 
    Beeri MS, Silverman JM, Davis KL, Marin D, Grossman HZ et al. 2005. Type 2 diabetes is negatively associated with Alzheimer's disease neuropathology. J. Gerontol. A Biol. Sci. Med. Sci. 60:471–75
     [Google Scholar]
  17. 17. 
    Bennett DA 2017. Mixed pathologies and neural reserve: implications of complexity for Alzheimer disease drug discovery. PLOS Med 14:e1002256
     [Google Scholar]
  18. 18. 
    Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT et al. 2006. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 66:1837–44
     [Google Scholar]
  19. 19. 
    Bennett DA, Schneider JA, Bienias JL, Evans DA, Wilson RS 2005. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology 64:834–41
     [Google Scholar]
  20. 20. 
    Bennett DA, Schneider JA, Tang Y, Arnold SE, Wilson RS 2006. The effect of social networks on the relation between Alzheimer's disease pathology and level of cognitive function in old people: a longitudinal cohort study. Lancet Neurol 5:406–12
     [Google Scholar]
  21. 21. 
    Bennett DA, Wilson RS, Boyle PA, Buchman AS, Schneider JA 2012. Relation of neuropathology to cognition in persons without cognitive impairment. Ann. Neurol. 72:599–609
     [Google Scholar]
  22. 22. 
    Bennett DA, Wilson RS, Schneider JA, Evans DA, Mendes de Leon CF et al. 2003. Education modifies the relation of AD pathology to level of cognitive function in older persons. Neurology 60:1909–15
     [Google Scholar]
  23. 23. 
    Boyle PA, Buchman AS, Wilson RS, Yu L, Schneider JA, Bennett DA 2012. Effect of purpose in life on the relation between Alzheimer disease pathologic changes on cognitive function in advanced age. Arch. Gen. Psychiatry 69:499–504
     [Google Scholar]
  24. 24. 
    Boyle PA, Wilson RS, Yu L, Barr AM, Honer WG et al. 2013. Much of late life cognitive decline is not due to common neurodegenerative pathologies. Ann. Neurol. 74:478–89
     [Google Scholar]
  25. 25. 
    Boyle PA, Yu L, Wilson RS, Leurgans SE, Schneider JA, Bennett DA 2018. Person-specific contribution of neuropathologies to cognitive loss in old age. Ann. Neurol. 83:74–83
     [Google Scholar]
  26. 26. 
    Brayne C, Ince PG, Keage HAD, McKeith IG, Matthews FE et al. 2010. Education, the brain and dementia: neuroprotection or compensation?: EClipSE Collaborative Members. Brain 133:2210–16
     [Google Scholar]
  27. 27. 
    Brookmeyer R, Abdalla N 2018. Estimation of lifetime risks of Alzheimer's disease dementia using biomarkers for preclinical disease. Alzheimer's Dement 14:981–88
     [Google Scholar]
  28. 28. 
    Brookmeyer R, Abdalla N, Kawas CH, Corrada MM 2018. Forecasting the prevalence of preclinical and clinical Alzheimer's disease in the United States. Alzheimers Dement 14:121–29
     [Google Scholar]
  29. 29. 
    Brookmeyer R, Evans DA, Hebert L, Langa KM, Heeringa SG et al. 2011. National estimates of the prevalence of Alzheimer's disease in the United States. Alzheimers Dement 7:61–73
     [Google Scholar]
  30. 30. 
    Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM 2007. Forecasting the global burden of Alzheimer's disease. Alzheimer's Dement 3:186–91
     [Google Scholar]
  31. 31. 
    Brown BM, Peiffer JJ, Martins RN 2013. Multiple effects of physical activity on molecular and cognitive signs of brain aging: Can exercise slow neurodegeneration and delay Alzheimer's disease?. Mol. Psychiatry 18:864–74
     [Google Scholar]
  32. 32. 
    Brown BM, Peiffer JJ, Taddei K, Lui JK, Laws SM et al. 2013. Physical activity and amyloid-β plasma and brain levels: results from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing. Mol. Psychiatry 18:875–81
     [Google Scholar]
  33. 33. 
    Brown BM, Rainey-Smith SR, Dore V, Peiffer JJ, Burnham SC et al. 2018. Self-reported physical activity is associated with tau burden measured by positron emission tomography. J. Alzheimers Dis. 63:1299–305
     [Google Scholar]
  34. 34. 
    Buchman AS, Dawe RJ, Yu L, Lim A, Wilson RS et al. 2018. Brain pathology is related to total daily physical activity in older adults. Neurology 90:e1911–19
     [Google Scholar]
  35. 35. 
    Buchman AS, Schneider JA, Wilson RS, Bienias JL, Bennett DA 2006. Body mass index in older persons is associated with Alzheimer disease pathology. Neurology 67:1949–54
     [Google Scholar]
  36. 36. 
    Buchman AS, Wilson RS, Bienias JL, Shah RC, Evans DA, Bennett DA 2005. Change in body mass index and risk of incident Alzheimer disease. Neurology 65:892–97
     [Google Scholar]
  37. 37. 
    Cerasuolo JO, Cipriano LE, Sposato LA, Kapral MK, Fang J et al. 2017. Population-based stroke and dementia incidence trends: age and sex variations. Alzheimers Dement 13:1081–88
     [Google Scholar]
  38. 38. 
    Crane PK, Gibbons LE, Dams-O'Connor K, Trittschuh E, Leverenz JB et al. 2016. Association of traumatic brain injury with late-life neurodegenerative conditions and neuropathologic findings. JAMA Neurol 73:1062–69
     [Google Scholar]
  39. 39. 
    Crystal H, Dickson D, Fuld P, Masur D, Scott R et al. 1988. Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology 38:1682–87
     [Google Scholar]
  40. 40. 
    Cummings JL, Morstorf T, Zhong K 2014. Alzheimer's disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res. Ther. 6:37
     [Google Scholar]
  41. 41. 
    De Jager PL, Srivastava G, Lunnon K, Burgess J, Schalkwyk LC et al. 2014. Alzheimer's disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci. Nat. Neurosci 17:1156–63
     [Google Scholar]
  42. 42. 
    Del Ser T, Hachinski V, Merskey H, Munoz DG 1999. An autopsy-verified study of the effect of education on degenerative dementia. Brain 122:2309–19
     [Google Scholar]
  43. 43. 
    Derby CA, Katz MJ, Lipton RB, Hall CB 2017. Trends in dementia incidence in a birth cohort analysis of the Einstein Aging Study. JAMA Neurol 74:1345–51
     [Google Scholar]
  44. 44. 
    Dodge HH, Zhu J, Woltjer R, Nelson PT, Bennett DA et al. 2017. Risk of incident clinical diagnosis of Alzheimer's disease-type dementia attributable to pathology-confirmed vascular disease. Alzheimers Dement 13:613–23
     [Google Scholar]
  45. 45. 
    Donovan NJ, Okereke OI, Vannini P, Amariglio RE, Rentz DM et al. 2016. Association of higher cortical amyloid burden with loneliness in cognitively normal older adults. JAMA Psychiatry 73:1230–37
     [Google Scholar]
  46. 46. 
    Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P et al. 2016. Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria. Alzheimers Dement 12:292–323
     [Google Scholar]
  47. 47. 
    Dumurgier J, Paquet C, Benisty S, Kiffel C, Lidy C et al. 2010. Inverse association between CSF Aβ 42 levels and years of education in mild form of Alzheimer's disease: the cognitive reserve theory. Neurobiol. Dis. 40:456–59
     [Google Scholar]
  48. 48. 
    Fagan AM, Xiong C, Jasielec MS, Bateman RJ, Goate AM et al. 2014. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Sci. Transl. Med. 6:226ra30
     [Google Scholar]
  49. 49. 
    Farfel JM, Nitrini R, Suemoto CK, Grinberg LT, Ferretti RE et al. 2013. Very low levels of education and cognitive reserve: a clinicopathologic study. Neurology 81:650–57
     [Google Scholar]
  50. 50. 
    Farfel JM, Yu L, Buchman AS, Schneider JA, De Jager PL, Bennett DA 2016. Relation of genomic variants for Alzheimer disease dementia to common neuropathologies. Neurology 87:489–96
     [Google Scholar]
  51. 51. 
    Fitzpatrick AL, Kuller LH, Lopez OL, Diehr P, O'Meara ES et al. 2009. Midlife and late-life obesity and the risk of dementia: cardiovascular health study. Arch. Neurol. 66:336–42
     [Google Scholar]
  52. 52. 
    Fratiglioni L, Paillard-Borg S, Winblad B 2004. An active and socially integrated lifestyle in late life might protect against dementia. Lancet Neurol 3:343–53
     [Google Scholar]
  53. 53. 
    Gaiteri C, Mostafavi S, Honey CJ, De Jager PL, Bennett DA 2016. Genetic variants in Alzheimer disease—molecular and brain network approaches. Nat. Rev. Neurol. 12:413–27
     [Google Scholar]
  54. 54. 
    Ganguli M, Rodriguez EG 1999. Reporting of dementia on death certificates: a community study. J. Am. Geriatr. Soc. 47:842–49
     [Google Scholar]
  55. 55. 
    Garibotto V, Borroni B, Kalbe E, Herholz K, Salmon E et al. 2008. Education and occupation as proxies for reserve in aMCI converters and AD: FDG-PET evidence. Neurology 71:1342–49
     [Google Scholar]
  56. 56. 
    Gidicsin CM, Maye JE, Locascio JJ, Pepin LC, Philiossaint M et al. 2015. Cognitive activity relates to cognitive performance but not to Alzheimer disease biomarkers. Neurology 85:48–55
     [Google Scholar]
  57. 57. 
    Glymour MM, Brickman AM, Kivimaki M, Mayeda ER, Chêne G et al. 2018. Will biomarker-based diagnosis of Alzheimer's disease maximize scientific progress? Evaluating proposed diagnostic criteria. Eur. J. Epidemiol. 33:607–12
     [Google Scholar]
  58. 58. 
    Gottesman RF, Schneider ALC, Zhou Y, Coresh J, Green E et al. 2017. Association between midlife vascular risk factors and estimated brain amyloid deposition. JAMA 317:1443–50
     [Google Scholar]
  59. 59. 
    Head D, Bugg JM, Goate AM, Fagan AM, Mintun MA et al. 2012. Exercise engagement as a moderator of the effects of APOE genotype on amyloid deposition. Arch. Neurol. 69:636–43
     [Google Scholar]
  60. 60. 
    Head E, Corrada MM, Kahle-Wrobleski K, Kim RC, Sarsoza F et al. 2009. Synaptic proteins, neuropathology and cognitive status in the oldest-old. Neurobiol. Aging 30:1125–34
     [Google Scholar]
  61. 61. 
    Hebert LE, Bienias JL, Aggarwal NT, Wilson RS, Bennett DA et al. 2010. Change in risk of Alzheimer disease over time. Neurology 75:786–91
     [Google Scholar]
  62. 62. 
    Hebert LE, Weuve J, Scherr PA, Evans DA 2013. Alzheimer disease in the United States (2010–2050) estimated using the 2010 census. Neurology 80:1778–83
     [Google Scholar]
  63. 63. 
    Heitner J, Dickson D 1997. Diabetics do not have increased Alzheimer-type pathology compared with age-matched control subjects. A retrospective postmortem immunocytochemical and histofluorescent study. Neurology 49:1306–11
     [Google Scholar]
  64. 64. 
    Honer WG, Barr AM, Sawada K, Thornton AE, Morris MC et al. 2012. Cognitive reserve, presynaptic proteins and dementia in the elderly. Transl. Psychiatry 2:e114
     [Google Scholar]
  65. 65. 
    Iacono D, Markesbery WR, Gross M, Pletnikova O, Rudow G et al. 2009. The Nun study: clinically silent AD, neuronal hypertrophy, and linguistic skills in early life. Neurology 73:665–73
     [Google Scholar]
  66. 66. 
    Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B et al. 2018. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement 14:535–62
     [Google Scholar]
  67. 67. 
    Jack CR, Wiste HJ, Weigand SD, Knopman DS, Vemuri P et al. 2015. Age, sex, and APOE ε4 effects on memory, brain structure, and β-amyloid across the adult life span. JAMA Neurol 72:511–19
     [Google Scholar]
  68. 68. 
    James BD, Bennett DA, Boyle PA, Leurgans S, Schneider JA 2012. Dementia from Alzheimer disease and mixed pathologies in the oldest old. JAMA 307:1798–800
     [Google Scholar]
  69. 69. 
    James BD, Leurgans SE, Hebert LE, Scherr PA, Yaffe K, Bennett DA 2014. Contribution of Alzheimer disease to mortality in the United States. Neurology 82:1045–50
     [Google Scholar]
  70. 70. 
    James BD, Wilson RS, Boyle PA, Trojanowski JQ, Bennett DA, Schneider JA 2016. TDP-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia. Brain 139:2983–93
     [Google Scholar]
  71. 71. 
    Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P et al. 2015. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 313:1924–38
     [Google Scholar]
  72. 72. 
    Jellinger KA 2004. Head injury and dementia. Curr. Opin. Neurol. 17:719–23
     [Google Scholar]
  73. 73. 
    Joas E, Bäckman K, Gustafson D, Östling S, Waern M et al. 2012. Blood pressure trajectories from midlife to late life in relation to dementia in women followed for 37 years. Hypertension 59:796–801
     [Google Scholar]
  74. 74. 
    Ju Y-E, Lucey BP, Holtzman DM 2014. Sleep and Alzheimer disease pathology—a bidirectional relationship. Nat. Rev. Neurol. 10:115–19
     [Google Scholar]
  75. 75. 
    Kantarci K, Lowe V, Przybelski SA, Weigand SD, Senjem ML et al. 2012. APOE modifies the association between Aβ load and cognition in cognitively normal older adults. Neurology 78:232–40
     [Google Scholar]
  76. 76. 
    Kapasi A, DeCarli C, Schneider JA 2017. Impact of multiple pathologies on the threshold for clinically overt dementia. Acta Neuropathol 134:171–86
     [Google Scholar]
  77. 77. 
    Kapasi A, Schneider JA 2016. Vascular contributions to cognitive impairment, clinical Alzheimer's disease, and dementia in older persons. Biochim. Biophys. Acta 1862:878–86
     [Google Scholar]
  78. 78. 
    Katzman R, Terry R, DeTeresa R, Brown T, Davies P et al. 1988. Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann. Neurol. 23:138–44
     [Google Scholar]
  79. 79. 
    Khachaturian ZS, Petersen RC, Snyder PJ, Khachaturian AS, Aisen P et al. 2011. Developing a global strategy to prevent Alzheimer's disease: Leon Thal Symposium 2010. Alzheimers Dement 7:127–32
     [Google Scholar]
  80. 80. 
    Kim J, Basak JM, Holtzman DM 2009. The role of apolipoprotein E in Alzheimer's disease. Neuron 63:287–303
     [Google Scholar]
  81. 81. 
    Kok E, Haikonen S, Luoto T, Huhtala H, Goebeler S et al. 2009. Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age. Ann. Neurol. 65:650–57
     [Google Scholar]
  82. 82. 
    Landau SM, Marks SM, Mormino EC, Rabinovici GD, Oh H et al. 2012. Association of lifetime cognitive engagement and low β-amyloid deposition. Arch. Neurol. 69:623–29
     [Google Scholar]
  83. 83. 
    Langa KM 2015. Is the risk of Alzheimer's disease and dementia declining?. Alzheimers Res. Ther. 7:34
     [Google Scholar]
  84. 84. 
    Langa KM, Larson EB, Karlawish JH, Cutler DM, Kabeto MU et al. 2008. Trends in the prevalence and mortality of cognitive impairment in the United States: Is there evidence of a compression of cognitive morbidity?. Alzheimers Dement 4:134–44
     [Google Scholar]
  85. 85. 
    Law LL, Rol RN, Schultz SA, Dougherty RJ, Edwards DF et al. 2018. Moderate intensity physical activity associates with CSF biomarkers in a cohort at risk for Alzheimer's disease. Alzheimers Dement 10:188–95
     [Google Scholar]
  86. 86. 
    Liang KY, Mintun MA, Fagan AM, Goate AM, Bugg JM et al. 2010. Exercise and Alzheimer's disease biomarkers in cognitively normal older adults. Ann. Neurol. 68:311–18
     [Google Scholar]
  87. 87. 
    Lim AS, Klein H-U, Yu L, Chibnik LB, Ali S et al. 2017. Diurnal and seasonal molecular rhythms in human neocortex and their relation to Alzheimer's disease. Nat. Commun. 8:14931
     [Google Scholar]
  88. 88. 
    Lim AS, Yu L, Kowgier M, Schneider JA, Buchman AS, Bennett DA 2013. Modification of the relationship of the apolipoprotein E ε4 allele to the risk of Alzheimer disease and neurofibrillary tangle density by sleep. JAMA Neurol 70:1544–51
     [Google Scholar]
  89. 89. 
    Lim YY, Mormino EC, Alzheimer's Dis. Neuroimaging Initiat. 2017. APOE genotype and early beta-amyloid accumulation in older adults without dementia. Neurology 89:1028–34
     [Google Scholar]
  90. 90. 
    Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G 2013. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat. Rev. Neurol. 9:106–18
     [Google Scholar]
  91. 91. 
    Liu JL, Hlavka JP, Hillestad R, Mattke S 2017. Assessing the preparedness of the U.S. health care system infrastructure for an Alzheimer's treatment. Rep., RAND Corp Santa Monica, CA: https://www.rand.org/pubs/research_reports/RR2272.html
  92. 92. 
    Makin S 2018. The amyloid hypothesis on trial. Nature 559:S4–7
     [Google Scholar]
  93. 93. 
    Manton KC, Gu XL, Ukraintseva SV 2005. Declining prevalence of dementia in the U.S. elderly population. Adv. Gerontol. 16:30–37
     [Google Scholar]
  94. 94. 
    Matthews DC, Davies M, Murray J, Williams S, Tsui WH et al. 2014. Physical activity, Mediterranean diet and biomarkers-assessed risk of Alzheimer's: a multi-modality brain imaging study. Adv. Mol. Imaging 4:43–57
     [Google Scholar]
  95. 95. 
    Matthews FE, Arthur A, Barnes LE, Bond J, Jagger C et al. 2013. A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II. Lancet 382:1405–12
     [Google Scholar]
  96. 96. 
    Matthews FE, Brayne C, Lowe J, McKeith I, Wharton SB, Ince P 2009. Epidemiological pathology of dementia: attributable-risks at death in the Medical Research Council Cognitive Function and Ageing Study. PLOS Med 6:e1000180
     [Google Scholar]
  97. 97. 
    McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM 1984. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34:939–44
     [Google Scholar]
  98. 98. 
    McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR et al. 2011. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7:263–69
     [Google Scholar]
  99. 99. 
    Mielke MM, Savica R, Wiste HJ, Weigand SD, Vemuri P et al. 2014. Head trauma and in vivo measures of amyloid and neurodegeneration in a population-based study. Neurology 82:70–76
     [Google Scholar]
  100. 100. 
    Mondragón JD, Celada-Borja C, Barinagarrementeria-Aldatz F, Burgos-Jaramillo M, Barragán-Campos HM 2016. Hippocampal volumetry as a biomarker for dementia in people with low education. Dement. Geriatr. Cogn. Disord. Extra 6:486–99
     [Google Scholar]
  101. 101. 
    Monsell SE, Mock C, Fardo DW, Bertelsen S, Cairns NJ et al. 2017. Genetic comparison of symptomatic and asymptomatic persons with Alzheimer disease neuropathology. Alzheimer Dis. Assoc. Disord. 31:232–38
     [Google Scholar]
  102. 102. 
    Monsell SE, Mock C, Hassenstab J, Roe CM, Cairns NJ et al. 2014. Neuropsychological changes in asymptomatic persons with Alzheimer disease neuropathology. Neurology 83:434–40
     [Google Scholar]
  103. 103. 
    Mormino EC, Betensky RA, Hedden T, Schultz AP, Ward A et al. 2014. Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology 82:1760–67
     [Google Scholar]
  104. 104. 
    Morris MC, Brockman J, Schneider JA, Wang Y, Bennett DA et al. 2016. Association of seafood consumption, brain mercury level, and APOE ε4 status with brain neuropathology in older adults. JAMA 315:489–97
     [Google Scholar]
  105. 105. 
    Morris MC, Schneider JA, Li H, Tangney CC, Nag S et al. 2015. Brain tocopherols related to Alzheimer's disease neuropathology in humans. Alzheimers Dement 11:32–39
     [Google Scholar]
  106. 106. 
    Mortimer JA, Snowdon DA, Markesbery WR 2003. Head circumference, education and risk of dementia: findings from the Nun Study. J. Clin. Exp. Neuropsychol. 25:671–79
     [Google Scholar]
  107. 107. 
    Mostafavi S, Gaiteri C, Sullivan SE, White CC, Tasaki S et al. 2018. A molecular network of the aging human brain provides insights into the pathology and cognitive decline of Alzheimer's disease. Nat. Neurosci. 21:811–19
     [Google Scholar]
  108. 108. 
    Murray AD, Staff RT, McNeil CJ, Salarirad S, Ahearn TS et al. 2011. The balance between cognitive reserve and brain imaging biomarkers of cerebrovascular and Alzheimer's diseases. Brain 134:3687–96
     [Google Scholar]
  109. 109. 
    Neu SC, Pa J, Kukull W, Beekly D, Kuzma A et al. 2017. Apolipoprotein E genotype and sex risk factors for Alzheimer disease: a meta-analysis. JAMA Neurol 74:1178–89
     [Google Scholar]
  110. 110. 
    Okonkwo OC, Schultz SA, Oh JM, Larson J, Edwards D et al. 2014. Physical activity attenuates age-related biomarker alterations in preclinical AD. Neurology 83:1753–60
     [Google Scholar]
  111. 111. 
    Oveisgharan S, Buchman AS, Yu L, Farfel J, Hachinski V et al. 2018. APOE ε2ε4 genotype, incident AD and MCI, cognitive decline, and AD pathology in older adults. Neurology 90:24 https://doi.org/10.1212/WNL.0000000000005677
    [Crossref] [Google Scholar]
  112. 112. 
    Prince M, Ali GC, Guerchet M, Prina AM, Albanese E, Wu YT 2016. Recent global trends in the prevalence and incidence of dementia, and survival with dementia. Alzheimers Res. Ther. 8:23
     [Google Scholar]
  113. 113. 
    Reed BR, Dowling M, Tomaszewski Farias S, Sonnen J, Strauss M et al. 2011. Cognitive activities during adulthood are more important than education in building reserve. J. Int. Neuropsychol. Soc. 17:615–24
     [Google Scholar]
  114. 114. 
    Reiman EM, Chen K, Liu X, Bandy D, Yu M et al. 2009. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. PNAS 106:6820–25
     [Google Scholar]
  115. 115. 
    Rentz DM, Locascio JJ, Becker JA, Moran EK, Eng E et al. 2010. Cognition, reserve, and amyloid deposition in normal aging. Ann. Neurol. 67:353–64
     [Google Scholar]
  116. 116. 
    Resnick SM, Sojkova J, Zhou Y, An Y, Ye W et al. 2010. Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology 74:807–15
     [Google Scholar]
  117. 117. 
    Riudavets MA, Iacono D, Resnick SM, O'Brien R, Zonderman AB et al. 2007. Resistance to Alzheimer's pathology is associated with nuclear hypertrophy in neurons. Neurobiol. Aging 28:1484–92
     [Google Scholar]
  118. 118. 
    Roe CM, Fagan AM, Grant EA, Marcus DS, Benzinger TLS et al. 2011. Cerebrospinal fluid biomarkers, education, brain volume, and future cognition. Arch. Neurol. 68:1145–51
     [Google Scholar]
  119. 119. 
    Roe CM, Mintun MA, D'Angelo G, Xiong C, Grant EA, Morris JC 2008. Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake. Arch. Neurol. 65:1467–71
     [Google Scholar]
  120. 120. 
    Roe CM, Xiong C, Miller JP, Cairns NJ, Morris JC 2008. Interaction of neuritic plaques and education predicts dementia. Alzheimer Dis. Assoc. Disord. 22:188–93
     [Google Scholar]
  121. 121. 
    Roe CM, Xiong C, Miller JP, Morris JC 2007. Education and Alzheimer disease without dementia: support for the cognitive reserve hypothesis. Neurology 68:223–28
     [Google Scholar]
  122. 122. 
    Saczynski JS, Pfeifer LA, Masaki K, Korf ES, Laurin D et al. 2006. The effect of social engagement on incident dementia: the Honolulu-Asia Aging Study. Am. J. Epidemiol. 163:433–40
     [Google Scholar]
  123. 123. 
    Satizabal CL, Beiser AS, Chouraki V, Chêne G, Dufouil C, Seshadri S 2016. Incidence of dementia over three decades in the Framingham Heart Study. N. Engl. J. Med. 374:523–32
     [Google Scholar]
  124. 124. 
    Scarmeas N, Levy G, Tang MX, Manly J, Stern Y 2001. Influence of leisure activity on the incidence of Alzheimer's disease. Neurology 57:2236–42
     [Google Scholar]
  125. 125. 
    Schneider JA, Aggarwal NT, Barnes L, Boyle P, Bennett DA 2009. The neuropathology of older persons with and without dementia from community versus clinic cohorts. J. Alzheimers Dis. 18:691–701
     [Google Scholar]
  126. 126. 
    Schneider JA, Arvanitakis Z, Bang W, Bennett DA 2007. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 69:2197–204
     [Google Scholar]
  127. 127. 
    Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA 2009. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann. Neurol. 66:200–8
     [Google Scholar]
  128. 128. 
    Schneider JA, Wilson RS, Bienias JL, Evans DA, Bennett DA 2004. Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology. Neurology 62:1148–55
     [Google Scholar]
  129. 129. 
    Schrijvers EM, Verhaaren BF, Koudstaal PJ, Hofman A, Ikram MA, Breteler MM 2012. Is dementia incidence declining? Trends in dementia incidence since 1990 in the Rotterdam Study. Neurology 78:1456–63
     [Google Scholar]
  130. 130. 
    Sloane PD, Zimmerman S, Suchindran C, Reed P, Wang L et al. 2002. The public health impact of Alzheimer's disease, 2000–2050: potential implication of treatment advances. Annu. Rev. Public Health 23:213–31
     [Google Scholar]
  131. 131. 
    Smith AD, Yaffe K 2014. Dementia (including Alzheimer's disease) can be prevented: statement supported by international experts. J. Alzheimers Dis. 38:699–703
     [Google Scholar]
  132. 132. 
    Sperling R, Mormino E, Johnson K 2014. The evolution of preclinical Alzheimer's disease: implications for prevention trials. Neuron 84:608–22
     [Google Scholar]
  133. 133. 
    Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S et al. 2011. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7:280–92
     [Google Scholar]
  134. 134. 
    Stern Y 2002. What is cognitive reserve? Theory and research application of the reserve concept. J. Int. Neuropsychol. Soc. 8:448–60
     [Google Scholar]
  135. 135. 
    Stern Y, Gurland B, Tatemichi TK, Tang MX, Wilder D, Mayeux R 1994. Influence of education and occupation on the incidence of Alzheimer's disease. JAMA 271:1004–10
     [Google Scholar]
  136. 136. 
    Taylor C, Greenlund S, McGuire L, Lu H, Croft JB 2017. Deaths from Alzheimer's disease—United States, 1999–2014. MMWR 66:521–26
     [Google Scholar]
  137. 137. 
    Toledo JB, Toledo E, Weiner MW, Jack CR, Jagust W et al. 2012. Cardiovascular risk factors, cortisol, and amyloid-β deposition in Alzheimer's Disease Neuroimaging Initiative. Alzheimers Dement 8:483–89
     [Google Scholar]
  138. 138. 
    Valenzuela M, Brayne C, Sachdev P, Wilcock G, Matthews F et al. 2011. Cognitive lifestyle and long-term risk of dementia and survival after diagnosis in a multicenter population-based cohort. Am. J. Epidemiol. 173:1004–12
     [Google Scholar]
  139. 139. 
    Vemuri P, Knopman DS, Lesnick TG, Przybelski SA, Mielke MM et al. 2017. Evaluation of amyloid protective factors and Alzheimer disease neurodegeneration protective factors in elderly individuals. JAMA Neurol 74:718–26
     [Google Scholar]
  140. 140. 
    Vemuri P, Lesnick TG, Przybelski SA, Knopman DS, Lowe VJ et al. 2017. Age, vascular health, and Alzheimer disease biomarkers in an elderly sample. Ann. Neurol. 82:706–18
     [Google Scholar]
  141. 141. 
    Vemuri P, Lesnick TG, Przybelski SA, Knopman DS, Roberts RO et al. 2012. Effect of lifestyle activities on Alzheimer disease biomarkers and cognition. Ann. Neurol. 72:730–38
     [Google Scholar]
  142. 142. 
    Vemuri P, Weigand SD, Przybelski SA, Knopman DS, Smith GE et al. 2011. Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition. Brain 134:1479–92
     [Google Scholar]
  143. 143. 
    Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA et al. 2013. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 12:357–67
     [Google Scholar]
  144. 144. 
    Vos SJ, Xiong C, Visser PJ, Jasielec MS, Hassenstab J et al. 2013. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol 12:957–65
     [Google Scholar]
  145. 145. 
    Wada M, Noda Y, Shinagawa S, Chung JK, Sawada K et al. 2018. Effect of education on Alzheimer's disease-related neuroimaging biomarkers in healthy controls, and participants with mild cognitive impairment and Alzheimer's disease: a cross-sectional study. J. Alzheimers Dis. 63:861–69
     [Google Scholar]
  146. 146. 
    Wang H-X, Xu W, Pei J-J 2012. Leisure activities, cognition and dementia. Biochim. Biophys. Acta 1822:482–91
     [Google Scholar]
  147. 147. 
    Wang HX, Karp A, Winblad B, Fratiglioni L 2002. Late-life engagement in social and leisure activities is associated with a decreased risk of dementia: a longitudinal study from the Kungsholmen project. Am. J. Epidemiol. 155:1081–87
     [Google Scholar]
  148. 148. 
    Weiner MW, Harvey D, Hayes J, Landau SM, Aisen PS et al. 2017. Effects of traumatic brain injury and posttraumatic stress disorder on development of Alzheimer's disease in Vietnam veterans using the Alzheimer's Disease Neuroimaging Initiative: preliminary report. Alzheimers Dement 3:177–88
     [Google Scholar]
  149. 149. 
    Weuve J, Hebert LE, Scherr PA, Evans DA 2014. Deaths in the United States among persons with Alzheimer's disease (2010–2050). Alzheimers Dement 10:e40–46
     [Google Scholar]
  150. 150. 
    White L 2009. Brain lesions at autopsy in older Japanese-American men as related to cognitive impairment and dementia in the final years of life: a summary report from the Honolulu-Asia aging study. J. Alzheimers Dis. 18:713–25
     [Google Scholar]
  151. 151. 
    Wilson RS, Boyle PA, Buchman AS, Yu L, Arnold SE, Bennett DA 2011. Harm avoidance and risk of Alzheimer's disease. Psychosom. Med. 73:690–96
     [Google Scholar]
  152. 152. 
    Wilson RS, Boyle PA, Levine SR, Yu L, Hoganson GM et al. 2014. Harm avoidance and cerebral infarction. Neuropsychology 28:305–11
     [Google Scholar]
  153. 153. 
    Wilson RS, Boyle PA, Yu L, Barnes LL, Schneider JA, Bennett DA 2013. Life-span cognitive activity, neuropathologic burden, and cognitive aging. Neurology 81:314–21
     [Google Scholar]
  154. 154. 
    Wilson RS, Capuano AW, Boyle PA, Hoganson GM, Hizel LP et al. 2014. Clinical-pathologic study of depressive symptoms and cognitive decline in old age. Neurology 83:702–9
     [Google Scholar]
  155. 155. 
    Wilson RS, Krueger KR, Arnold SE, Schneider JA, Kelly JF et al. 2007. Loneliness and risk of Alzheimer disease. Arch. Gen. Psychiatry 64:234–40
     [Google Scholar]
  156. 156. 
    Wilson RS, Mendes De Leon CF, Barnes LL, Schneider JA, Bienias JL et al. 2002. Participation in cognitively stimulating activities and risk of incident Alzheimer disease. JAMA 287:742–48
     [Google Scholar]
  157. 157. 
    Wilson RS, Nag S, Boyle PA, Hizel LP, Yu L et al. 2013. Neural reserve, neuronal density in the locus ceruleus, and cognitive decline. Neurology 80:1202–8
     [Google Scholar]
  158. 158. 
    Wilson RS, Schneider JA, Arnold SE, Bienias JL, Bennett DA 2007. Conscientiousness and the incidence of Alzheimer disease and mild cognitive impairment. Arch. Gen. Psychiatry 64:1204–12
     [Google Scholar]
  159. 159. 
    Wirth M, Villeneuve S, La Joie R, Marks SM, Jagust WJ 2014. Gene-environment interactions: lifetime cognitive activity, APOE genotype, and β-amyloid burden. J. Neurosci. 34:8612–17
     [Google Scholar]
  160. 160. 
    Wu YT, Beiser AS, Breteler MMB, Fratiglioni L, Helmer C et al. 2017. The changing prevalence and incidence of dementia over time—current evidence. Nat. Rev. Neurol. 13:327–39
     [Google Scholar]
  161. 161. 
    Yu L, Boyle PA, Segawa E, Leurgans S, Schneider JA et al. 2015. Residual decline in cognition after adjustment for common neuropathologic conditions. Neuropsychology 29:335–43
     [Google Scholar]
  162. 162. 
    Yu L, Petyuk VA, Gaiteri C, Mostafavi S, Young-Pearse T et al. 2018. Targeted brain proteomics uncover multiple pathways to Alzheimer's dementia. Ann. Neurol. 84:78–88
     [Google Scholar]
/content/journals/10.1146/annurev-publhealth-040218-043758
Loading
Causes and Patterns of Dementia: An Update in the Era of Redefining Alzheimer's Disease
Annual Review of Public Health 40, 65 (2019); https://doi.org/10.1146/annurev-publhealth-040218-043758
/content/journals/10.1146/annurev-publhealth-040218-043758
/content/journals/10.1146/annurev-publhealth-040218-043758
Loading

Data & Media loading...

  • Article Type: Review Article

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error